AI Analyst Summary
Vertex Pharmaceuticals commands a dominant position in cystic fibrosis (CF) treatment with its Trikafta/Kaftrio franchise driving 12.5% revenue growth, while a maturing pipeline — including non-opioid pain drug suzetrigine and gene-editing programs — offers meaningful optionality beyond CF. Forward P/E compression to 23.6x and near-universal analyst bullishness (23 of 29 analysts rated Buy or better) underpin a constructive long-term setup. The key risk is pipeline execution: failure or delays in late-stage programs outside CF could materially reset the growth narrative and premium valuation.
Fundamentals
Pe
Trailing P/E: 29.5x | Forward P/E: 23.6x · 4.0/5
Trailing P/E of 29.5x is reasonable for a high-quality biotech with a dominant franchise; forward P/E compresses to 23.6x, suggesting continued earnings expansion. In-line to modestly below sector peers given VRTX's durable growth profile.
Peg
PEG: 1.73 · 3.0/5
PEG of 1.73 sits in neutral territory — not cheap, not stretched. Growth expectations are moderate at ~8% YoY earnings growth, keeping the PEG above the compelling <1.0 threshold but well below the danger zone of >3.0.
Analyst Rating
Strong Buy consensus (1.6) · 5.0/5
Consensus rating of 1.6 on the inverted scale reflects overwhelmingly bullish sentiment, with 23 Buy ratings vs. 5 Hold and just 1 Sell across 25 analysts. A broad, high-conviction institutional endorsement.
Earnings Trend
EPS Growth +8.0% YoY | Revenue Growth +12.5% YoY · 3.0/5
Earnings growth of 8% YoY is positive but modest for a biotech leader. Revenue growing faster at 12.5% signals operating leverage potential ahead, though the gap between top-line and bottom-line growth warrants monitoring. Growth is stable but not accelerating.
Price Target Beat
EPS Beat Rate: 2 of 4 quarters · 2.0/5
Only 2 of the last 4 quarters saw EPS beats, indicating inconsistent near-term execution relative to street estimates. This is below average and tempers confidence in management's ability to consistently exceed expectations.
Management
Mixed execution signal · 3.0/5
Strong analyst conviction and a premium valuation suggest respect for management's long-term capital allocation and pipeline strategy. However, a 50% EPS beat rate over recent quarters reflects mixed near-term execution, keeping the management score at neutral.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.